Contents

Talk:Sarepta Therapeutics

This is the talk page for discussing improvements to the Sarepta Therapeutics article. This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic. New to Wikipedia? Welcome! Learn to edit; get help. Assume good faith Be polite and avoid personal attacks Be welcoming to newcomers Seek dispute resolution if needed Article policies Neutral point of view No original research Verifiability

Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL

This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects:

Oregon Low‑importance This article is within the scope of WikiProject Oregon, a collaborative effort to improve the coverage of the U.S. stateofOregon on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.OregonWikipedia:WikiProject OregonTemplate:WikiProject OregonOregon articles Low This article has been rated as Low-importance on the project's importance scale. The current collaborations of the month are Women's History Month: Create or improve articles for women listed at Oregon Women of Achievement (modern) or Women of the West, Oregon chapter (historical). Companies Low‑importance This article is within the scope of WikiProject Companies, a collaborative effort to improve the coverage of companies on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.CompaniesWikipedia:WikiProject CompaniesTemplate:WikiProject Companiescompany articles Low This article has been rated as Low-importance on the project's importance scale. WikiProject Companies To-do: Here are some tasks awaiting attention: Article requests : Wikipedia:Requested articles/Business and economics/Companies Assess : Category:Unassessed company articles Copyedit : Category:Company articles needing attention Infobox : Category:Company articles needing infoboxes Maintain : Portal:Companies Stubs : Help expand stub articles located at Category:Company stubs Other : Tag company articles with the {{portal|Companies}} template Tag company talk pages with the {{WikiProject Companies}} project banner Answer requests for comments

Not sure if the following belongs in the article. I looked at a few other pharmaceutical company articles and they did not have this sort of info. I'm not an expert on corporate articles so please let me know if I'm wrong. If replaced, the info really needs to be cleaned up and formatted. Katr67 23:19, 21 August 2006 (UTC) Modified by Katr67 19:09, 8 December 2006 (UTC)[reply]

Key Statistics[edit]

Market Cap (intraday): 97.65M,Enterprise Value (29-Sep-05)3: 66.79M, Trailing P/E (ttm, intraday): N/A, Forward P/E (fye 31-Dec-06) 1: N/A, PEG Ratio (5 yr expected): N/A, Price/Sales (ttm): 261.09, Price/Book (mrq): 2.56, Enterprise Value/Revenue (ttm)3: 176.10, Enterprise Value/EBITDA (ttm)3: -3.556

Financial highlights[edit]

Fiscal Year Fiscal Year Ends: 31-Dec Most Recent Quarter (mrq): 30-Jun-05 Profitability Profit Margin (ttm): -5413.09% Operating Margin (ttm): -5472.21% Management Effectiveness Return on Assets (ttm): -32.97% Return on Equity (ttm): -55.04% Income Statement Revenue (ttm): 379.25K Revenue Per Share (ttm): 0.01 Qtrly Revenue Growth (yoy): 8.40% Gross Profit (ttm): 969.87K EBITDA (ttm): -18.78M Net Income Avl to Common (ttm): -20.53M Diluted EPS (ttm): -0.52 Qtrly Earnings Growth (yoy): -31.00%

Balance Sheet[edit]

Total Cash (mrq): 32.19M Total Cash Per Share (mrq): 0.728 Total Debt (mrq): 0 Total Debt/Equity (mrq): 0 Current Ratio (mrq): 16.833 Book Value Per Share (mrq): 0.874 Cash Flow Statement From Operations (ttm): -18.15M Free Cashflow (ttm): -12.69M

Key Executives & Pay Exercised[edit]

• Dr. Denis R. Burger Ph.D., 61

Chairman, Chief Exec. Officer and Member of Exec. Committee $ 450.00K $ 0

• Mr. Alan P. Timmins , 45

Pres, Chief Operating Officer, Director and Member of Exec. Committee $ 385.00K $ 0

• Mr. Mark M. Webber , 50

Chief Financial Officer, Principal Accounting Officer, Chief Information Officer and Controller $ 250.00K $ 0

• Dr. Patrick L. Iversen Ph.D., 49

Sr. VP of R&D $ 300.00K $ 0

• Dr. Dwight D. Weller Ph.D., 54

Sr. VP of Chemistry and Manufacturing, Director and Member of Exec. Committee $ 250.00K $ 0

The notes above are very out-of-date, it would be reasonable to remove them from this page.

I just changed the statement that Summerton "discovered" Morpholinos so that it now states he conceived of them and then, with Weller, invented them. Also, Morpholinos were described as synthetic RNA, but their structure is quite different so I changed the description to synthetic analog of RNA.

JonMoulton (talk) 22:05, 9 July 2009 (UTC)[reply]